Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M17ibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ezO|AvPSEQvF2= MnjtO|IhcA>? NHjCeWZFVVOR MYLJR|UxRTBwMESg{txO NX\QNYUzOjZzM{[2PFQ>
LS174T M{XrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzJZYsxNjVizszN NEDrRo04OiCq MnzSSG1UVw>? M2myTWlEPTB;MD6wOUDPxE1? NX:wS41jOjZzM{[2PFQ>
T84 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H6NVAvPSEQvF2= Mon2O|IhcA>? NXzpSVl4TE2VTx?= M2\RfGlEPTB;MD6wPUDPxE1? MUSyOlE{PjZ6NB?=
LS180 NFvU[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHVNE42KM7:TR?= MlTpO|IhcA>? NXT4VnNwTE2VTx?= NYe5Vod5UUN3ME2xJO69VQ>? MnfNNlYyOzZ4OES=
SW948 M{W2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmwMlUh|ryP M2mzRVczKGh? M4DzcWROW09? NHnu[pZKSzVyPUGg{txO MkHlNlYyOzZ4OES=
HCT15 NXrFWoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LkfFAvPSEQvF2= NWi0Z4huPzJiaB?= MnS1SG1UVw>? NWLEdYxTUUN3MEywMlQh|ryP NFvleHQzPjF|Nk[4OC=>
DLD-1 NVvxRnBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnFW5pkOC53IN88US=> MnfOO|IhcA>? Mm\wSG1UVw>? MkTRTWM2ODxyLkig{txO M2D5ZlI3OTN4Nki0
MIP-101 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PFe|AvPSEQvF2= MnvkO|IhcA>? NWKxWWYxTE2VTx?= NH;RUnhKSzVyPUGg{txO MoLaNlYyOzZ4OES=
SNU1544 M2DVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX72Uno2OC53IN88US=> MUG3NkBp NUj6[ldlTE2VTx?= NEPCTFdKSzVyPUGg{txO NGTsNlkzPjF|Nk[4OC=>
OCI-Ly10 NVqyVGhDS3m2b4TvfIlkKEG|c3H5 MX:3NkBp NIPkVG1FVVOR NW\rcI5CUUN3ME2wMlA2QCEQvF2= M4HuXlI2QDd6M{Ox
SU-DHL2 NHHPcJdEgXSxdH;4bYMhSXO|YYm= NYPBWoU{PzJiaB?= MVfEUXNQ MXnJR|UxRTBwMEGg{txO MnfQNlU5Pzh|M{G=
OCI-LY7 MYfDfZRwfG:6aXOgRZN{[Xl? MmLmO|IhcA>? MV\EUXNQ NX\HNmI1UUN3ME2wMlA5OSEQvF2= NUnKc25{OjV6N{izN|E>
SU-DHL6 MWrDfZRwfG:6aXOgRZN{[Xl? MWm3NkBp MUnEUXNQ MnHaTWM2OD1yLkS4NkDPxE1? M1XxUVI2QDd6M{Ox
Jeko-1 NFnVeVREgXSxdH;4bYMhSXO|YYm= NWLqR|NuPzJiaB?= M3fT[2ROW09? NEjxN4JKSzVyPUCuNFI6KM7:TR?= NYPnOnJ2OjV6N{izN|E>
JVM-2 MnjDR5l1d3SxeHnjJGF{e2G7 MYG3NkBp MUDEUXNQ MkPDTWM2OD1yLkCxJO69VQ>? M3vDTVI2QDd6M{Ox
Rec-1 MWLDfZRwfG:6aXOgRZN{[Xl? MY[3NkBp MlrsSG1UVw>? NV:5c|ZlUUN3ME2wMlA5PyEQvF2= Mm\CNlU5Pzh|M{G=
Z-138 NVnacGdnS3m2b4TvfIlkKEG|c3H5 M335SlczKGh? MUfEUXNQ NUTaWGhkUUN3ME2wMlAyOyEQvF2= MmLENlU5Pzh|M{G=
H9 NYnFVlViS3m2b4TvfIlkKEG|c3H5 M1v5UVczKGh? MkDQSG1UVw>? NXPPPY86UUN3ME2wMlYh|ryP M2XFO|I2QDd6M{Ox
HH Mmr5R5l1d3SxeHnjJGF{e2G7 NVLSTVVoPzJiaB?= M2rMVWROW09? NVTJWodVUUN3ME2wMlch|ryP MV2yOVg4QDN|MR?=
DND41 M1XoWWN6fG:2b4jpZ{BCe3OjeR?= NX3hTI8zPzJiaB?= NUPTdoNDTE2VTx?= M3GwfGlEPTB;MD6xJO69VQ>? MmTpNlU5Pzh|M{G=
CCL119 M2PnfWN6fG:2b4jpZ{BCe3OjeR?= M37JU|czKGh? NGraWo5FVVOR NY\vSYlEUUN3ME2wMlA3OiEQvF2= MVSyOVg4QDN|MR?=
J.Cam 1.6 NXTYZ5VDS3m2b4TvfIlkKEG|c3H5 Mny4O|IhcA>? MWDEUXNQ NYHEd3FpUUN3ME2wMlExPSEQvF2= NVfoO453OjV6N{izN|E>
Sup-T1 MYLDfZRwfG:6aXOgRZN{[Xl? NV3XdINwPzJiaB?= MoDwSG1UVw>? MnjmTWM2OD1{LkG0NkDPxE1? NIrSRo4zPTh5OEOzNS=>
Tib 152 MWfDfZRwfG:6aXOgRZN{[Xl? NFXYSYI4OiCq MWfEUXNQ M37rNWlEPTB;MD64JO69VQ>? NXP4U4RLOjV6N{izN|E>
MCF7 MVzGeY5kfGmxbjDBd5NigQ>? M4\VRVUh|ryP M1TY[VI1KGh? NX\4PW86TE2VTx?= M2fVSWlv\HWlZYOgS|IwVSCjcoLld5Q> NVvJR5V6OjV6M{S0NFE>
MDA-MB-231 M3W3[mZ2dmO2aX;uJGF{e2G7 M{Da[VUh|ryP NUjrc4lHOjRiaB?= NES4NZVFVVOR M1;pfWlv\HWlZYOgS|MwVSCjcoLld5Q> MlfHNlU5OzR2MEG=
MCF7 M3OzcWZ2dmO2aX;uJGF{e2G7 MYq1JO69VQ>? NITSTYczPCCq NW\hUYE3TE2VTx?= NIL0cldF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy MkHCNlU5OzR2MEG=
MCF7 NILIPJBHfW6ldHnvckBCe3OjeR?= NHu0eHM2KM7:TR?= NWGydWhqOjRiaB?= MYHEUXNQ NX7afVc3TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? NXO1fJRVOjV6M{S0NFE>
MCF7 MUjGeY5kfGmxbjDBd5NigQ>? MYC1JO69VQ>? NHPORoQzPCCq MlLHSG1UVw>? MUfE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz MmDNNlU5OzR2MEG=
MCF7 NV;jRVZmTnWwY4Tpc44hSXO|YYm= NX\tZnlmPSEQvF2= MVSyOEBp NYHKO4psTE2VTx?= NXPDT5lTUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? NGnTUZkzPTh|NESwNS=>
MCF7 M4fyS2Z2dmO2aX;uJGF{e2G7 NWP5XZRDPSEQvF2= MV[yOEBp NXv4V45CTE2VTx?= MVrJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? MVGyOVg{PDRyMR?=
MDA-MB-231 NInxbldHfW6ldHnvckBCe3OjeR?= M2XhWVUh|ryP NIjFcpQzPCCq MVnEUXNQ NFezXFBF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NYTmOYlyOjV6M{S0NFE>
MDA-MB-231 M3faV2Z2dmO2aX;uJGF{e2G7 Mm\XNUDPxE1? M1zNS|I1KGh? M2LUVmROW09? MV\JcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> MYiyOVg{PDRyMR?=
MDA-MB-231 NY\F[WZ5TnWwY4Tpc44hSXO|YYm= NYr5dpN4PSEQvF2= MVSyOEBp NYXtVoZETE2VTx?= NInIZpBF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx M1;DR|I2QDN2NECx
MDA-MB-231 MWHGeY5kfGmxbjDBd5NigQ>? NUf1cIxKPSEQvF2= M2f6blI1KGh? M3Pp[2ROW09? NYDwW25MUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? NV\oS3NSOjV6M{S0NFE>
MDA-MB-231 M{nuWmZ2dmO2aX;uJGF{e2G7 NH\CUmo2KM7:TR?= NYC5fmxMOjRiaB?= Mn\PSG1UVw>? M1G0cWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= MUOyOVg{PDRyMR?=
MDA-MB-231 NEPEWmJHfW6ldHnvckBCe3OjeR?= MVm1JO69VQ>? Mn3ONlQhcA>? MnH1SG1UVw>? MYfJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz MYSyOVg{PDRyMR?=
MCF7 NGXqdllCeG:ydH;zbZMhSXO|YYm= MkXCOUDPxE1? MlXKNlQhcA>? M3fCZ2ROW09? MUnJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? MWiyOVg{PDRyMR?=
MDA-MB-231 NH6wXm5CeG:ydH;zbZMhSXO|YYm= MUe1JO69VQ>? Mo\FNlQhcA>? NHvjOIRFVVOR M4P3XGlv\HWlZYOgZZBweHSxdHnjJIRm[XSq NWTCUZllOjV6M{S0NFE>
MCF7 MWHGeY5kfGmxbjDBd5NigQ>? M3\qXlEh|ryP NIDpd|Y4OiCq NGXkTmxFVVOR NUXrcGRJUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo NYn0cmFvOjV6M{S0NFE>
MDA-MB-231 NEjN[mVHfW6ldHnvckBCe3OjeR?= Mk\kNUDPxE1? NFzqb4c4OiCq MnzUSG1UVw>? M1TIV2lv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= MWWyOVg{PDRyMR?=
U-2 OS MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv3OVAh|ryP NFP4Z2czPCCq M2XvXWROW09? NU\XVWZLUUN3ME2xOk43KM7:TR?= Ml;SNlU4QTJ6MUG=
MG-63 NF;temlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfnWZl[PTBizszN M33uU|I1KGh? MXjEUXNQ MXnJR|UxRTlwNTFOwG0> M1jnOFI2Pzl{OEGx
U-2 OS MlzuRZBweHSxc3nzJGF{e2G7 NGG5TlY2KM7:TR?= NF7qPWEzPCCq M4XYb2ROW09? MkD6TY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NFXxcZkzPTd7MkixNS=>
MG-63 NXPRd2d1SXCxcITvd4l{KEG|c3H5 M2HvclUh|ryP NFTaWpkzPCCq MX7EUXNQ M2XaUWlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> NIDuWZkzPTd7MkixNS=>
U-2 OS MmrPSpVv[3Srb36gRZN{[Xl? M3zFeFUh|ryP NHfpcoszPCCq MXzEUXNQ MVfQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NGjEWYozPTd7MkixNS=>
MG-63 MoLySpVv[3Srb36gRZN{[Xl? NG\CTW82KM7:TR?= MVOyOEBp Mlm4SG1UVw>? M4HDO3Bzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? M3S1dlI2Pzl{OEGx
PANC-1 NHXPVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[zVYxlPTBizszN MkDCNlQhcA>? NVzQUoM1TE2VTx?= NFrU[npKSzVyPUeuNUDPxE1? MXGyOVY{OjJ{NR?=
BxPC-3 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTVOVAh|ryP MUmyOEBp NGTvbFZFVVOR NI\sOJdKSzVyPU[uPEDPxE1? M4frWlI2PjN{MkK1
PANC-1 NEDZZpJHfW6ldHnvckBCe3OjeR?= MWK1JO69VQ>? MmfZNlQhcA>? M{fFR2ROW09? M33Tfmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NXfubo1JOjV4M{KyNlU>
BxPC-3 NEHr[W9HfW6ldHnvckBCe3OjeR?= NIHRbXk2KM7:TR?= NFzYd3QzPCCq NX21SoxFTE2VTx?= MonCTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm M1PEc|I2PjN{MkK1
PANC-1 MX;GeY5kfGmxbjDBd5NigQ>? MV:1JO69VQ>? MYWyOEBp NVnGPHBOTE2VTx?= MYjJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> MkXtNlU3OzJ{MkW=
BxPC-3 M4TRO2Z2dmO2aX;uJGF{e2G7 Moq1OUDPxE1? NHSxW|kzPCCq M2ezeGROW09? NUjVfIpFUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NXzEUmZGOjV4M{KyNlU>
SKOV3 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmxNFAh|ryP NEPnRoMzPCCq MlLBSG1UVw>? NIm4ZnBKSzVyPUKwMlQ5KM7:TR?= MYOyOVYzPDd3MB?=
OVCAR4 M1PsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX63VoJJOTByIN88US=> MV2yOEBp M37lUWROW09? M{DlTGlEPTB;MkKuNVMh|ryP NED3cZUzPTZ{NEe1NC=>
SKOV3 M1LVXGZ2dmO2aX;uJGF{e2G7 MonSOUDPxE1? NFvOSo04OiCq Mmj1SG1UVw>? MkHYTY5lfWOnczDHNk9OKGG{cnXzeC=> M4TlOFI2PjJ2N{Ww
OVCAR4 NIXRNpZHfW6ldHnvckBCe3OjeR?= NG[xWVE2KM7:TR?= NUD0d21QPzJiaB?= MUnEUXNQ M2rEUWlv\HWlZYOgS|IwVSCjcoLld5Q> M2jlXVI2PjJ2N{Ww
SKOV3 Mn31RZBweHSxc3nzJGF{e2G7 NEThbow2KM7:TR?= NVz5Tox7OjRiaB?= NULFemFiTE2VTx?= M3KxPWlv\HWlZYOgZZBweHSxc3nz MWOyOVYzPDd3MB?=
OVCAR4 NX;rT2hbSXCxcITvd4l{KEG|c3H5 NGLzRo42KM7:TR?= M3zDe|I1KGh? M2X0ZmROW09? NXHlcop7UW6mdXPld{BieG:ydH;zbZM> NGfBeXgzPTZ{NEe1NC=>
AGS M3X5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO4NlUh|ryP NH20WnczPCCq NUnS[4RnTE2VTx?= M4jXcWlEPTB;MUmuNFkh|ryP M{D3V|I2PjB7OUKz
NCI-N78 NUK3ZY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X0VlI2KM7:TR?= NFmxdJczPCCq Mn7zSG1UVw>? MnnqTWM2OD1{Nj6zN{DPxE1? MlPuNlU3ODl7MkO=
AGS MlTIRZBweHSxc3nzJGF{e2G7 M4P0SlUh|ryP NVn0dZd1OjRiaB?= MkCzSG1UVw>? MXzJcoR2[2W|IHHwc5B1d3Orcx?= Ml;yNlU3ODl7MkO=
NCI-N78 MYDBdI9xfG:|aYOgRZN{[Xl? MUS1JO69VQ>? MmDTNlQhcA>? MYfEUXNQ NIfDWoRKdmS3Y3XzJIFxd3C2b4Ppdy=> NX3ScnFIOjV4MEm5NlM>
AGS NIX0S4ZHfW6ldHnvckBCe3OjeR?= NU\pPJplPSEQvF2= MXWyOEBp NULYbpZkTE2VTx?= MYrJcoR2[2W|IITo[UBifXSxcHjh[5k> MUOyOVYxQTl{Mx?=
NCI-N78 MlvISpVv[3Srb36gRZN{[Xl? MWO1JO69VQ>? NYPtdYpROjRiaB?= NYe0[oEyTE2VTx?= M2S0dmlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NYLsSXJyOjV4MEm5NlM>
HSC-3 NV\0c3dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPJUmYyKM7:TR?= NVfYeIxSPDhiaB?= NXfiNlRTUUN3ME2wMlU1KM7:TR?= MUWyOVM3PjF2Mx?=
GB30 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nzeVEh|ryP NV;1UHppPyCm M2C1RWROW09? M{DxbWlEPTB;MD6wNVEh|ryP NH;INGIzPTFyNkSyPC=>
GB9 NUTvVJVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHOfVlUOSEQvF2= M2PSXlch\A>? MV;EUXNQ NFzSTHFKSzVyPUCuNFI1KM7:TR?= MVqyOVExPjR{OB?=
GB169 M3znN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6xJO69VQ>? NX63SIFiPyCm NGPLfW5FVVOR M3u1OmlEPTB;MD6wN|Ih|ryP MXiyOVExPjR{OB?=
T24 MULGeY5kfGmxbjDBd5NigQ>? MWmxJO69VQ>? NYjVN2Z2PDhiaB?= NUG0em9iTE2VTx?= NYPHW3BSUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MorTNlM1ODN4M{O=
RT4 M2jmWWZ2dmO2aX;uJGF{e2G7 MUOxJO69VQ>? NHrqcGs1QCCq NGHkS4dFVVOR NISzZ|VKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 Mor5NlM1ODN4M{O=
UM-UC-3 MVfGeY5kfGmxbjDBd5NigQ>? NIXCfHMyKM7:TR?= NE\WSng1QCCq NF;pWWdFVVOR MnTzTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M2jFTFI{PDB|NkOz
T24 MVTBdI9xfG:|aYOgRZN{[Xl? M{HBdVMvOTZizszN MmO0PVYhcA>? MkfiSG1UVw>? MY\JR|UxRTBwMEOwOkDPxE1? MYGyN|QxOzZ|Mx?=
RT4 M1v4PWFxd3C2b4Ppd{BCe3OjeR?= NUnlbWdFOy5zNjFOwG0> MUe5OkBp NYT1ZnRvTE2VTx?= NF\CZ3VKSzVyPUCuNVE6QCEQvF2= MnzvNlM1ODN4M{O=
UM-UC-3 NHfQbIlCeG:ydH;zbZMhSXO|YYm= NXTrT3Q3Oy5zNjFOwG0> NXmwRmw1QTZiaB?= MVrEUXNQ MlrJTWM2OD1yLkC0OFkh|ryP MVSyN|QxOzZ|Mx?=
OVCAR-5 Mlq3SpVv[3Srb36gRZN{[Xl? MXm1NEBvVQ>? MUHJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>? M17lUFI{OzN2M{K3
SKOV3ip2 MmnxSpVv[3Srb36gRZN{[Xl? M1P2OVUxKG6P M3n6[2lvcGmkaYTzJINmdGxibXnndoF1cW:w NEnXT3EzOzN|NEOyOy=>
S462 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[1NVAxKM7:TR?= M335O|czKGh? NFvSS5hFVVOR MnHERZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MkLKNlM{OjhzMUS=
2884 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjvNVAxKM7:TR?= NVvrZWp6PzJiaB?= MX;EUXNQ NFv5WJRCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NF7oUXgzOzN{OEGxOC=>
2885 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xNFAh|ryP MnvyO|IhcA>? NEHYWnRFVVOR MlXFRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MnLPNlM{OjhzMUS=
CRL-2396 NWfn[3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLu[2oyODBizszN NIPoXJp4[XSnch?= MoTVTWM2OD1yLkC5NkDPxE1? MkTlNlMyPTN3MkS=
TIB-48 NWfkTZB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XGRVExOCEQvF2= MVz3ZZRmeg>? MoDMTWM2OD1yLkC4PEDPxE1? NGjUOWQzOzF3M{WyOC=>
CRL-2396 M3j2dGN6fG:2b4jpZ{BCe3OjeR?= M2\tWFEh|ryP MVi0PEBp NYPDVnRNf2G2ZYK= NW\Jbng3UW6mdXPld{BieG:ydH;zbZM> M12yZlI{OTV|NUK0
TIB-48 MmjsR5l1d3SxeHnjJGF{e2G7 M2P2XVEh|ryP MYO0PEBp MXL3ZZRmeg>? Mli4TY5lfWOnczDhdI9xfG:|aYO= NGTwOGQzOzF3M{WyOC=>
AGS NUnzRY9wS3m2b4TvfIlkKEG|c3H5 NVTp[lJ6OC53IN88US=> MWGyOEBp M13vRWROW09? NXzZcpNyTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= NUnjNZZ1OjJ7N{K2NVE>
FLO-1 MkXPR5l1d3SxeHnjJGF{e2G7 MWiwMlUh|ryP MXWyOEBp MYDEUXNQ MXLE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? MmOwNlI6PzJ4MUG=
OE33 MWjDfZRwfG:6aXOgRZN{[Xl? NGXhVIMxNjVizszN MnjZNlQhcA>? MXTEUXNQ NUHIdmlRTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= NVrtbmxrOjJ7N{K2NVE>
SKLMS MoexR5l1d3SxeHnjJGF{e2G7 MWm3OUBvVQ>? NFm3coM6PiCq M1PPcGlv\HWlZYOgZZBweHSxc3nz MmHZNlI5OjF7OUe=
Leio285 MVXDfZRwfG:6aXOgRZN{[Xl? NIrpR5A4PSCwTR?= MmTsPVYhcA>? MWfJcoR2[2W|IHHwc5B1d3Orcx?= NVnid4U2OjJ6MkG5PVc>
Mes-Sa Ml3MR5l1d3SxeHnjJGF{e2G7 MXu3OUBvVQ>? NYe4eoZKQTZiaB?= NGfVdZFKdmS3Y3XzJIFxd3C2b4Ppdy=> NGTxe2wzOjh{MUm5Oy=>
DAOY NWDKc3k5S3m2b4TvfIlkKEG|c3H5 M3zYT|ExKM7:TR?= Mnr6O|IhcA>? NYDDUWpGTE2VTx?= NV3LenZKUUN3ME2wMlA1KM7:TR?= NFTyVpczOjZ4OUOzOS=>
IMR32 M4PBZ2N6fG:2b4jpZ{BCe3OjeR?= NIjkO5oyOCEQvF2= M4XGfVczKGh? Ml\nSG1UVw>? MnTOTWM2OD1yLkCzJO69VQ>? NF3lRWszOjZ4OUOzOS=>
Molt-4 MWnDfZRwfG:6aXOgRZN{[Xl? MmS2NVAh|ryP M{PNelczKGh? MojDSG1UVw>? NGTheIRKSzVyPUCuNFIh|ryP NXHDe3QzOjJ4NkmzN|U>
MOLM-13 NUTMXJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuN{DPxE1? MUG3NkBp NX31XmlrTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M1;Ld|IzPDh6MkS5
HL-60 NIXP[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzhOZQ{KM7:TR?= MWS3NkBp Mm[xSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NW\KZZNnOjJ2OEiyOFk>
MV4-11 NIW2OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGzJO69VQ>? MY[3NkBp MoDtSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MXSyNlQ5QDJ2OR?=
SKM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mzflMh|ryP MW[3NkBp NGOzd2RFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MXmyNlQ5QDJ2OR?=
SH2 NUPPWlhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfSUnQ{KM7:TR?= NVn0fot{PzJiaB?= M{TBcWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M3XOOlIzPDh6MkS5
NOMO-1 NUToO4U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSzJO69VQ>? M1rqTVczKGh? NUXlcJRKTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NFvQ[oEzOjR6OEK0PS=>
OCL-AML2 M4XQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPxXVY{KM7:TR?= M2HVZ|czKGh? M133TmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NGfqTGkzOjR6OEK0PS=>
PL-21 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXniV4xPOyEQvF2= MVK3NkBp MWTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NEP5Z2MzOjR6OEK0PS=>
KG-1 M4rNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKzJO69VQ>? MY[3NkBp M1\XdmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MWWyNlQ5QDJ2OR?=
A172 NVfSZ2VWS3m2b4TvfIlkKEG|c3H5 NIHMUXEyODBizszN NUjleG5ZOjRiaB?= M4\ZdGROW09? M1nodWlEPTB;MD6xNlAh|ryP MoS5NlIzPzR|OUm=
U87 M3u2fGN6fG:2b4jpZ{BCe3OjeR?= MYqxNFAh|ryP MYqyOEBp NXvUSJVtTE2VTx?= M4PYOGlEPTB;MD6xNFUh|ryP M1PubVIzOjd2M{m5
U251 NIC5blNEgXSxdH;4bYMhSXO|YYm= MWqxNFAh|ryP MnvDNlQhcA>? NEfVd|RFVVOR M{XnR2lEPTB;MD6xNFAh|ryP NWW4NXF3OjJ{N{SzPVk>
T98 M3TBXWN6fG:2b4jpZ{BCe3OjeR?= NEO5OYgyODBizszN M{LPOlI1KGh? MkfySG1UVw>? M37QU2lEPTB;MD6xNlUh|ryP M4jrOFIzOjd2M{m5
LN18 NYS1[WVYS3m2b4TvfIlkKEG|c3H5 M3XEc|ExOCEQvF2= MU[yOEBp M3G4fGROW09? NVrDbJZHUUN3ME2wMlIyOCEQvF2= MUOyNlI4PDN7OR?=
LN443 MoD6R5l1d3SxeHnjJGF{e2G7 NEfWcnAyODBizszN NHvkTmozPCCq NYHnSVV6TE2VTx?= MYTJR|UxRTBwMkKwJO69VQ>? NFzWcXczOjJ5NEO5PS=>
HF66 NVX2cJE1S3m2b4TvfIlkKEG|c3H5 MnnTNVAxKM7:TR?= M4f2SFI1KGh? NGHiR|NFVVOR NUHQWJNOUUN3ME2wMlIzPSEQvF2= NHzQcIUzOjJ5NEO5PS=>
HF2303 NHS4ZmNEgXSxdH;4bYMhSXO|YYm= NXLTdm44OTByIN88US=> M3LEXVI1KGh? MVHEUXNQ MVfJR|UxRTBwME[wJO69VQ>? MmnwNlIzPzR|OUm=
HF2359 NXTvfHN5S3m2b4TvfIlkKEG|c3H5 NHn5[JYyODBizszN MmTmNlQhcA>? NXXUdJVtTE2VTx?= M4q0NmlEPTB;MD6wOlAh|ryP NIjzcG8zOjJ5NEO5PS=>
HF2414 MlnDR5l1d3SxeHnjJGF{e2G7 NX;Z[FdYOTByIN88US=> M3j2[|I1KGh? NEfCbW9FVVOR MXLJR|UxRTBwMEiwJO69VQ>? MXqyNlI4PDN7OR?=
A-673 NWjCbpVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v3SlExKM7:TR?= NH7jXJA6PiCq Ml\vSG1UVw>? Mlf0TWM2OD1yLkCzNkDPxE1? MnnrNlE1PDh3OUG=
TC-32 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\0NVAh|ryP MWi5OkBp NEHWdnhFVVOR NYLFfVVbUUN3ME2wMlA{QSEQvF2= NWTiOJdtOjF2NEi1PVE>
TC-71 NFzkPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDQcVZzOTBizszN NHu1TIg6PiCq M3H0SmROW09? M33iZmlEPTB;MD6xNFIh|ryP MViyNVQ1QDV7MR?=
SK-N-MC NW\2c3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixNEDPxE1? M2DzfFk3KGh? NVzrcZQ2TE2VTx?= M3;sUGlEPTB;MD6wO|Ih|ryP NGjqPHgzOTR2OEW5NS=>
CHLA-9 NVrFd|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULJ[4QyOTBizszN MlvhPVYhcA>? MWPEUXNQ NGXoNW9KSzVyPUCuNFE5KM7:TR?= MlTNNlE1PDh3OUG=
CHLA-10 NHuwXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxNEDPxE1? M4npd|k3KGh? NE\UcG5FVVOR M2jtT2lEPTB;MD6wOlAh|ryP NGjZSIkzOTR2OEW5NS=>
CHLA-25 M{XGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrIN4hvOTBizszN NHTZXGk6PiCq NVf6eno6TE2VTx?= MkHCTWM2OD1yLkG2PEDPxE1? Ml3WNlE1PDh3OUG=
CHLA-32 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrCUIIyOCEQvF2= MnrTPVYhcA>? NEXVSllFVVOR MYTJR|UxRTBwMUO2JO69VQ>? MnSwNlE1PDh3OUG=
CHLA-56 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TDUFExKM7:TR?= NFvCOm46PiCq MVzEUXNQ NX;MV|RJUUN3ME2xNEDPxE1? MVKyNVQ1QDV7MR?=
CHLA-258 M2HTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTNNVAh|ryP M1PNNlk3KGh? MYDEUXNQ MonxTWM2OD1yLkGzNkDPxE1? MWeyNVQ1QDV7MR?=
COG-E-352 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNEDPxE1? NF7xbXo6PiCq NYHudpM{TE2VTx?= MYXJR|UxRTBwMESzJO69VQ>? M{DrXVIyPDR6NUmx
CHLA-90 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvJRZQyOCEQvF2= M{fETVk3KGh? NIfTdYhFVVOR MojJTWM2OD1yLkC2NUDPxE1? M4rpeFIyPDR6NUmx
CHLA-119 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXF[pgyOCEQvF2= M2HpTFk3KGh? NULIVlBWTE2VTx?= M{jVT2lEPTB;MD6wNlIh|ryP NY\mOXR[OjF2NEi1PVE>
CHLA-122 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT0NVAh|ryP NW\LfIpsQTZiaB?= MY\EUXNQ MmD5TWM2OD1yLkCxPUDPxE1? NUHGSXBOOjF2NEi1PVE>
CHLA-136 NF7aPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[xOpFVOTBizszN MVe5OkBp M2HQbmROW09? MVHJR|UxRTBwMEO5JO69VQ>? MX2yNVQ1QDV7MR?=
CHLA-140 M37HOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0WlExKM7:TR?= M3q2clk3KGh? M{DzUWROW09? NUTSXZRrUUN3ME2wMlAzPiEQvF2= M3G3TVIyPDR6NUmx
LA-N-6 M2LU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? MkXiPVYhcA>? M3PWeGROW09? NUDkOmV{UUN3ME2wMlA2PCEQvF2= M3T3ZlIyPDR6NUmx
NB-1643 M1rQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxNEDPxE1? M2LLSVk3KGh? NXzRPXhGTE2VTx?= MlH4TWM2OD1yLkCzO{DPxE1? M4jlfFIyPDR6NUmx
NB-EBc1 NVHsflhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HCblExKM7:TR?= NXfPUlV1QTZiaB?= MWTEUXNQ M1qwUGlEPTB;MD6wOVAh|ryP MXSyNVQ1QDV7MR?=
SK-N-BE-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqxZ2gyOCEQvF2= NXnH[ZFDQTZiaB?= MVfEUXNQ NFXiNWJKSzVyPUCuNFI5KM7:TR?= MlvENlE1PDh3OUG=
SK-N-BE-2 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrzd|BCOTBizszN MoHXPVYhcA>? NVHRS4RVTE2VTx?= MXrJR|UxRTBwMEO2JO69VQ>? NEP0bHEzOTR2OEW5NS=>
SMS-KAN NGHxXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxNEDPxE1? M3HRVlk3KGh? NWHqdGNFTE2VTx?= MkOyTWM2OD1yLkCzOEDPxE1? M3qydlIyPDR6NUmx
SMS-KANR NUjyPYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTrTXFQOTBizszN NUjkVJpRQTZiaB?= M3PPWWROW09? MUfJR|UxRTBwMEK2JO69VQ>? NUnk[VRHOjF2NEi1PVE>
SMS-KCN NYnObld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;SNVAh|ryP M3rPblk3KGh? MoPwSG1UVw>? MUPJR|UxRTBwMEG5JO69VQ>? NFTJWIYzOTR2OEW5NS=>
SMS-KCNR NUnWcJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{THOFExKM7:TR?= NHn6OG46PiCq M{XCWmROW09? NHP0[mxKSzVyPUCuNFExKM7:TR?= MVuyNVQ1QDV7MR?=
SMS-LHN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HqS|ExKM7:TR?= M1faWVk3KGh? NILLVllFVVOR M37keWlEPTB;MD6wN|Ih|ryP NEmxWlUzOTR2OEW5NS=>
SMS-MSN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNEDPxE1? MYC5OkBp MlmwSG1UVw>? NFnFe41KSzVyPUCuNFIzKM7:TR?= MmnYNlE1PDh3OUG=
SMS-SAN Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfpNVAh|ryP NX;DXFNWQTZiaB?= M2PIXGROW09? MYrJR|UxRTBwMEKwJO69VQ>? MnG1NlE1PDh3OUG=
Granta-4 M{Wy[GN6fG:2b4jpZ{BCe3OjeR?= MYixNEDPxE1? NHqwNHM4KGR? M3j1TGlEPTB;MD6wOFAh|ryP M{jmdFIyOjlzOE[3
DB NIXs[3BEgXSxdH;4bYMhSXO|YYm= Ml31NVAh|ryP NYLQfWExPyCm MWHJR|UxRTBwMESyJO69VQ>? NVTKZm1VOjF{OUG4Olc>
RL NUS1W5RxS3m2b4TvfIlkKEG|c3H5 MlzkNVAh|ryP MoDtO{Bl NILze2RKSzVyPUCuNFE2KM7:TR?= NFXZWFAzOTJ7MUi2Oy=>
K562 NYTLS3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TXWlExKM7:TR?= NU\LdXBFQTZiaB?= MWrJR|UxRTBwMEi3JO69VQ>? NGTFU3gzOTB7MU[zNy=>
LAMA-84 NFjEOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL2NVAh|ryP MUi5OkBp NEnCSndKSzVyPUCuNFU4KM7:TR?= NIXzTVQzOTB7MU[zNy=>
MM15 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTPUGQ1KM7:TR?= NFG1fYw4OiCq M3T4OmROW09? NWLmV2t4UUN3ME2wMlE{KM7:TR?= NF;iTGIzODN6Mki0OC=>
OPM1 NFvhUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13EcVQh|ryP MVu3NkBp MUHEUXNQ MYTJR|UxRTBwMEOg{txO NIjrSJkzODN6Mki0OC=>
RPM1 NIfTb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn6WVU1KM7:TR?= M2LRSlczKGh? NEnJdZhFVVOR M{HD[mlEPTB;MUCuN|Ih|ryP MVKyNFM5Ojh2NB?=
INA6 M2nKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy0JO69VQ>? MXy3NkBp MkHiSG1UVw>? NVrHUZdiUUN3ME2wMlAxOiEQvF2= NWi0VVNKOjB|OEK4OFQ>
OPM2 NFzJc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPqWXA1KM7:TR?= MmLsO|IhcA>? NYHuXnp3TE2VTx?= M1vE[mlEPTB;ND6zO{DPxE1? MWmyNFM5Ojh2NB?=
MM1R M2SyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnmOEDPxE1? NVrSdlNIPzJiaB?= M36zVGROW09? MoDkTWM2OD1zLk[4JO69VQ>? NUDSV4FsOjB|OEK4OFQ>
DOX40 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXNepE1KM7:TR?= NYrvT|dSPzJiaB?= NFLRcpdFVVOR MUDJR|UxRTVwNEig{txO MVmyNFM5Ojh2NB?=
LR5 NFrac3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO0JO69VQ>? MYi3NkBp NHnwN|VFVVOR NUDXfJBvUUN3ME2yMlU{KM7:TR?= M4G4b|IxOzh{OES0
U266 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[1ZVQh|ryP MlK3O|IhcA>? MlzoSG1UVw>? NFXXWVJKSzVyPUGuOFMh|ryP NEXDN5ozODN6Mki0OC=>
RD M2jm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiwcmkyOCEQvF2= NXy1W4pUQTZiaB?= NWq5dVdpUUN3ME2wMlIzQCEQvF2= M1;tOVIxOTB6M{O4
Rh41 NInuZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjnc4oyOCEQvF2= MmLmPVYhcA>? Ml;PTWM2OD1yLkC5NEDPxE1? NYHZZmRVOjBzMEizN|g>
Rh30 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKxNEDPxE1? NHi4TXM6PiCq NXTp[WpmUUN3ME2wMlI{OCEQvF2= NHrrdYEzODFyOEOzPC=>
BT-12 M4fNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFWlExKM7:TR?= NXTQT25kQTZiaB?= M4n1VGlEPTB;MD6wOlAh|ryP M4DWW|IxOTB6M{O4
CHLA-266 NXK4b5hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TTTlExKM7:TR?= M4Cxflk3KGh? M2e0WmlEPTB;MD6wO|Ih|ryP NED6dlgzODFyOEOzPC=>
TC-71 NUfnTHpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfESIM3OTBizszN NV7uN3FMQTZiaB?= M{DkfGlEPTB;MD6xNFIh|ryP M3XUTlIxOTB6M{O4
SJ-GBM2 M2LMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7xdVIyOCEQvF2= NUfVVJNuQTZiaB?= NUDvelZxUUN3ME2wMlA2OCEQvF2= MkL5NlAyODh|M{i=
NALM-6 NHzFT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWxNEDPxE1? M3;5blk3KGh? M2\0dmlEPTB;MD6wOlIh|ryP NYO3bppHOjBzMEizN|g>
COG-LL-317 NGT0cXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jiPFExKM7:TR?= NGTReWo6PiCq MVfJR|UxRTBwMES3JO69VQ>? MWeyNFExQDN|OB?=
RS4-11 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jHW|ExKM7:TR?= NY\vU2FIQTZiaB?= NVnVbopKUUN3ME2wMlAyQCEQvF2= MVSyNFExQDN|OB?=
MOLT-4 M4XTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\WVVcyOCEQvF2= NVzhdJFWQTZiaB?= NIn5bYVKSzVyPUCuNFI3KM7:TR?= NIn2bIozODFyOEOzPC=>
CCRF-CEM NHXmSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCOlV[OTBizszN MWC5OkBp MojFTWM2OD1yLkC5OEDPxE1? MXeyNFExQDN|OB?=
Kasumi-1 NEfkNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\6ZmNJOTBizszN M{TXPVk3KGh? MXvJR|UxRTBwMUCzJO69VQ>? NVfuUYtTOjBzMEizN|g>
Karpas-299 NVjUOoJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zzOlExKM7:TR?= MVS5OkBp M2SwNmlEPTB;MD6wN|gh|ryP NIPkUmszODFyOEOzPC=>
Ramos-RA1 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNEDPxE1? NUHQToJbQTZiaB?= NUTUfGRLUUN3ME2wMlEzPyEQvF2= MlHMNlAyODh|M{i=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID